Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 585 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram-negative Bacterial Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

NCT00777790
View directory record Official record
Conditions
Meningitis, Meningococcemia
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 21 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
9
States / cities
Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Sep 30, 2026, 9:11 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

NCT06615375
View directory record Official record
Conditions
Shigellosis
Interventions
Shigella4V2, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
View directory record Official record
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

NCT00258895
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis
Interventions
DAPTACEL®: DTaP
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
649 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
22
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 30, 2026, 9:11 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Improving Clinic Delivery of HIV-related Anal Health Services

NCT07464236
View directory record Official record
Conditions
HIV, Gonorrhea, Chlamydia, Anal Cancer Squamous Cell
Interventions
PEACHES 2.0 Implementation Strategies
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Biloxi, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of the ID NOW™ CT/NG Test

NCT06395675
View directory record Official record
Conditions
Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Asymptomatic Condition
Interventions
ID NOW™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
14 Years and older
Enrollment
7,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

NCT01631201
View directory record Official record
Conditions
Chlamydia Trachomatis Infection
Interventions
Rifalazil 25 milligram, Azithromycin 1 gram
Drug
Lead sponsor
ActivBiotics Pharma, LLC
Industry
Eligibility
19 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867
View directory record Official record
Conditions
E Coli Infections, Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
Biological · Other
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional

Study and Treatment of Post Lyme Disease (STOP-LD)

NCT00000937
View directory record Official record
Conditions
Lyme Disease
Interventions
Antibiotics
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT00910351
View directory record Official record
Conditions
Pseudomonas Infection
Interventions
Ciprofloxacin (Cipro, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational

The Role of Bacteria and Genetic Variations in Cystic Fibrosis

NCT00043225
View directory record Official record
Conditions
Psuedomas Infection, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
4
States / cities
Bethesda, Maryland • Seattle, Washington • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 30, 2026, 9:11 AM EDT
Not yet recruiting Not applicable Interventional

Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy

NCT06542289
View directory record Official record
Conditions
Bell's Palsy, Ramsay Hunt Syndrome, Lyme Disease, Facial Palsy
Interventions
BlinkER device.
Device
Lead sponsor
Neurotrigger Ltd
Industry
Eligibility
22 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Deerfield Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea

NCT02210325
View directory record Official record
Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
solithromycin, ceftriaxone, azithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 4 Interventional

A Study of Doxycycline to Treat Chlamydial Infection

NCT05840159
View directory record Official record
Conditions
Chlamydial Infection
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Terminated Phase 3 Interventional Results available

Empiric Therapy of Mucopurulent Cervicitis (MPC)

NCT01072136
View directory record Official record
Conditions
Vaginitis Bacterial, Cervicitis
Interventions
Placebo, Azithromycin, Cefixime
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Birmingham, Alabama • Torrance, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

NCT04543877
View directory record Official record
Conditions
Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
Interventions
Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
Dietary Supplement · Biological
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational

Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit

NCT05171257
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
IV antibiotic treatment from prior, differing IV antibiotic treatment
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safer Sex Program for Young African-American Men

NCT01439503
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Trichomoniasis, Syphilis, HIV Infections
Interventions
Intervention
Behavioral
Lead sponsor
Richard Crosby
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational

A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies

NCT01319253
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
6 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents

NCT01629589
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 12 Years
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
8
States / cities
Sacramento, California • Bardstown, Kentucky • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational

Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species

NCT00518661
View directory record Official record
Conditions
Quinolone Resistance, ESBL, Klebsiella Species, Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 30, 2026, 9:11 AM EDT